(March 25, 2024, 3:11 PM EDT) -- WASHINGTON, D.C. — A molecular diagnostics company and its subsidiaries deemed liable by a jury for willfully infringing a patented method of preparing nucleic acids say they need more time to reply to a recent cross-appellant brief, in which the patent owners say there is “no support in the record” for the appellants’ “entire argument on appeal” that “a sequencing primer can only be a primer used to read out a sequence.”...